Matteo Porotto Selected Research

Paramyxoviridae Infections (Parainfluenza)

1/2021	Parainfluenza virus entry at the onset of infection.
1/2021	Engineering Protease-Resistant Peptides to Inhibit Human Parainfluenza Viral Respiratory Infection.
1/2020	Human parainfluenza virus fusion complex glycoproteins imaged in action on authentic viral surfaces.
1/2017	Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides.
3/2016	Features of Circulating Parainfluenza Virus Required for Growth in Human Airway.
2/2015	Electron tomography imaging of surface glycoproteins on human parainfluenza virus 3: association of receptor binding and fusion proteins before receptor engagement.
11/2014	Circulating clinical strains of human parainfluenza virus reveal viral entry requirements for in vivo infection.
10/2013	Interaction between the hemagglutinin-neuraminidase and fusion glycoproteins of human parainfluenza virus type III regulates viral growth in vivo.
1/2012	Mechanism of fusion triggering by human parainfluenza virus type III: communication between viral glycoproteins during entry.
1/2012	Adaptation of human parainfluenza virus to airway epithelium reveals fusion properties required for growth in host tissue.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matteo Porotto Research Topics

Disease

38	Infections 06/2022 - 05/2009
17	Paramyxoviridae Infections (Parainfluenza) 01/2021 - 02/2006
8	COVID-19 01/2022 - 07/2020
7	Virus Diseases (Viral Diseases) 01/2022 - 05/2009
6	Measles 06/2022 - 02/2015
3	Human Influenza (Influenza) 12/2021 - 02/2010
3	Subacute Sclerosing Panencephalitis (SSPE) 01/2021 - 01/2019
3	Croup 01/2020 - 01/2012
3	Pneumonia (Pneumonitis) 01/2020 - 01/2012
3	Bronchiolitis 01/2020 - 01/2012
2	Central Nervous System Infections (Central Nervous System Infection) 01/2021 - 01/2019
2	Respiratory Tract Infections (Respiratory Tract Infection) 01/2021 - 11/2014
2	Respiratory Syncytial Virus Infections 01/2020 - 01/2019
2	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2020 - 07/2010
2	Henipavirus Infections 01/2018 - 10/2010
1	Thrombosis (Thrombus) 01/2022
1	Persistent Infection 12/2021
1	Lung Diseases (Lung Disease) 01/2021
1	Encephalitis (Encephalitis, Rasmussen) 01/2019
1	Emerging Communicable Diseases (Emerging Infectious Diseases) 01/2012
1	Central Nervous System Diseases (CNS Diseases) 07/2010
1	Vesicular Stomatitis 11/2009
1	Malaria 05/2009
1	Anemia 08/2008

Drug/Important Bio-Agent (IBA)

22	Proteins (Proteins, Gene)FDA Link 06/2022 - 07/2009
21	Antiviral Agents (Antivirals)IBA 01/2022 - 07/2009
15	Peptides (Polypeptides)IBA 06/2022 - 07/2010
13	Glycoproteins (Glycoprotein)IBA 01/2021 - 05/2009
12	VaccinesIBA 01/2022 - 01/2012
8	LipopeptidesIBA 06/2022 - 01/2018
7	Neuraminidase (Sialidase)IBA 02/2015 - 02/2006
6	RNA (Ribonucleic Acid)IBA 06/2022 - 01/2012
6	Carrier Proteins (Binding Protein)IBA 01/2021 - 10/2013
5	Hemagglutinins (Hemagglutinin)IBA 12/2021 - 12/2011
5	CholesterolIBA 12/2013 - 07/2010
3	AntibodiesIBA 01/2021 - 07/2020
2	Neutralizing AntibodiesIBA 02/2022 - 01/2022
2	InterferonsIBA 10/2021 - 01/2020
2	Immunoglobulin M (IgM)IBA 01/2021 - 07/2020
2	Amino Acids FDA Link 01/2021 - 01/2019
2	Pharmaceutical PreparationsIBA 01/2021 - 11/2014
2	Immunoglobulin A (IgA)IBA 01/2021 - 07/2020
2	Immunoglobulin G (IgG)IBA 01/2021 - 07/2020
2	Peptide Hydrolases (Proteases)FDA Link 01/2021 - 01/2017
2	sialic acid receptorIBA 10/2013 - 12/2012
2	Zanamivir (Relenza)FDA Link 04/2007 - 02/2006
1	AerosolsIBA 06/2022
1	Complement System Proteins (Complement)IBA 02/2022
1	AnticoagulantsIBA 01/2022
1	Blood Proteins (Serum Proteins)IBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	SARS-CoV-2 spike proteinIBA 01/2021
1	LipidsIBA 01/2021
1	Single-Chain AntibodiesIBA 01/2021
1	Biological ProductsIBA 01/2020
1	HN ProteinIBA 01/2020
1	Phenylalanine (L-Phenylalanine)FDA Link 01/2020
1	Protein CIBA 10/2018
1	peptide AIBA 12/2011
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 07/2010
1	oplunofuspIBA 07/2010
1	GliotoxinIBA 11/2009
1	Viral HemagglutininsIBA 07/2009
1	Chloroquine (Aralen)FDA LinkGeneric 05/2009
1	TG101209IBA 08/2008

Therapy/Procedure

7	Therapeutics 02/2022 - 10/2010
2	Intranasal Administration 01/2021 - 11/2020
1	Transcutaneous Electric Nerve Stimulation (TENS) 10/2020